INTRODUCTION {#s1}
============

Prostate cancer (PCa) recently became the second most frequently diagnosed malignant tumor, and the fifth leading cause of cancer death in men throughout the world \[[@R1]\]. Extensive evidence showed that obesity was implicated in the onset and progression of PCa \[[@R2], [@R3]\], and increasing researches were conducted to discover the connections between them. Of note, the aberrant secretion and signaling of various adipokines, including leptin and adiponectin, was proved to be one of the plausible mechanisms for carcinogenesis in obese man \[[@R4], [@R5]\].

Epidemiological evidence showed that high levels of serum leptin (*LEP*) were associated with onset and progression of various cancers \[[@R4], [@R6], [@R7]\]. *In vitro* studies revealed that leptin and its downstream signaling might induce cell proliferation \[[@R8]\], inhibit apoptosis \[[@R9]\], and mediate metabolism \[[@R10]\]. On the contrary, study showed that adiponectin (*ADIPOQ*) inhibited proliferation and invasion of PCa cells \[[@R11]\]. Moreover, the adiponectin level was proved lower in patients with metastatic PCa compared to those with organ-confined diseases \[[@R12]\]. Both leptin and adiponectin relied on binding to their receptors, leptin receptor (*LEPR*) or adiponectin receptor 1/2 (*ADIPOR1/ADIPOR2*), to activate downstream signaling and functioning \[[@R13], [@R14]\].

By modulating the levels and functioning of leptin and adiponectin, the genetic factors (single nucleotide polymorphisms and microsatellites in *LEP*, *LEPR*, *ADIPOQ*, *ADIPOR1* and *ADIPOR2*) were demonstrated to affect the risk and aggressiveness of PCa \[[@R15]--[@R17]\]. Nevertheless, these studies were still insufficient and inconsistent. Therefore, we conducted an updated meta-analysis and pooled-review to better clarify the role of genetic variants in leptin, adiponectin and their receptors in PCa. The present study aimed to help developing better risk-assessment tools and targeted therapies in the field of PCa.

RESULTS {#s2}
=======

Study characteristics in the meta-analysis and pooled-review {#s2_1}
------------------------------------------------------------

As shown in Figure [1](#F1){ref-type="fig"}, a total of 133 published studies were identified from different database after initial search. We excluded 111 studies after title and abstract scanning, and enrolled two additional studies through manual reference searching. Then, a total of 24 studies were subject to full-text examination. Consequently, a total of 11 studies \[[@R18]--[@R28]\] were enrolled in the meta-analysis investigating the relationships between *LEP*/*LEPR*/*ADIPOQ*/*ADIPOR1*/*ADIPOR2* variants and total PCa risk (Table [1](#T1){ref-type="table"}), and ten studies \[[@R19], [@R23], [@R29]--[@R36]\] were included in the pooled-review discussing these polymorphisms\' impact on the aggressiveness of cancer (Table [2](#T2){ref-type="table"}).

![Flow chart of study selection and identification](oncotarget-07-81049-g001){#F1}

###### Characteristics of studies included in the meta-analysis

  Author         Year   Country    Ethnicity          Control source   Genotyping methods   Size (case/control)   Genetic polymorphisms   NOS                                                                                                                                      
  -------------- ------ ---------- ------------------ ---------------- -------------------- --------------------- ----------------------- ---------------------------------------------------------------------------------------------------------------------------------------- ---
  Kote-Jarai     2003   UK         Caucasian          PB               PCR-RFLP             271/277               *LEPR*                  rs1137100, rs1137101                                                                                                                     7
  Ribeiro        2004   Portugal   Caucasian          HB               PCR-RFLP             143/118               *LEP*                   rs7799039                                                                                                                                6
  Gade           2006   USA        NA                 NA               PCR-SSR              69/137                *LEP*                   D7S1875(Microsatellite)                                                                                                                  4
                                                                                                                  *LEPR*                  Exon-3(Microsatellite)                                                                                                                   
  Wang           2009   USA        Mixed              PB               TaqMan               258/258               *LEP*                   rs2167270                                                                                                                                9
                                                                                                                  *ADIPOQ*                rs1501299                                                                                                                                
  Moore          2009   Finland    Caucasian          PB               TaqMan               1041/1048             *LEP*                   rs7799039, rs2167270, rs1349419, rs12535708, rs12535747, rs791620                                                                        9
                                                                                                                  *LEPR*                  rs1137100, rs1887285, rs7883, rs7602                                                                                                     
                                                                                                                  *ADIPOQ*                rs182052, rs822393, rs2241766, rs17366473                                                                                                
  Beebe-Dimmer   2010   USA        African-American   PB               Taqman               131/344               *ADIPOQ*                rs266729, rs822395, rs822396, rs2241766, rs1501299                                                                                       6
                                                                                                                  *ADIPOR1*               rs2232853, rs1342387, rs7539542, rs10920531                                                                                              
  Kaklamani      2011   USA        Mixed              PB               Taqman               465/441               *ADIPOQ*                rs266729, rs822395, rs822396, rs1501299, rs2241766                                                                                       8
                                                                                                                  *ADIPOR1*               rs12733285, rs1342387, rs7539542, rs2232853, rs10920531                                                                                  
  Dhillon        2011   USA        Caucasian          PB               Taqman               1286/1267             *ADIPOQ*                rs266729, rs182052, rs168681205, rs168681209, rs822391, rs12495941, rs17366568, rs3821799, rs3774261, rs17366743, rs2082940, rs7639352   9
                                                                                                                  *ADIPOR1*               rs10920531, rs7539542, rs16850799, rs12733285, rs7514221                                                                                 
                                                                                                                  *ADIPOR2*               rs1029629, rs7975600, rs12826079, rs11061946, rs10773983, rs1058322, rs10773986, rs11061973, rs7967137, rs1044471, rs1044825             
  Ribeiro        2012   Portugal   Caucasian          HB               TaqMan/PCR-RFLP      449/557               *LEP*                   rs7799039                                                                                                                                7
                                                                                                                  *LEPR*                  rs1137100, rs8179183, rs1137101                                                                                                          
  Gu             2014   China      Asian              PB               Taqman               917/1036              *ADIPOQ*                rs3774262, rs266729, rs182052                                                                                                            9
  Nitta          2016   Japan      NA                 NA               NA                   198/122               *ADIPOQ*                rs2241766, rs266729, rs822395                                                                                                            4

*NOS* Newcastle-Ottawa Scale, *SNP* single nucleotide polymorphism, *PB* population-based, *HB* hospital-based, *NA* not available, *PCR* polymerase chain reaction, *RFLP* restriction fragment length polymorphism, *SSR* simple sequence repeats

Common synonyms for genetic polymorphisms: LEP G2548A(rs7799039), LEP A19G(rs2167270), LEPR K109R(rs1137100), LEPR Q223R(rs1137101), LEPR K656N (rs8179183)

###### Meta-analysis of multiple studies identifying the associations between *LEP/LEPR/ADIPOQ/ADIPOR1* polymorphisms and prostate cancer risk

  Genetic polymorphisms[^\#^](#tfn_003){ref-type="table-fn"}   No. of studies   Dominant model           Recessive model   Homozygote model         Heterozygote model   Allele contrast model                                                                      
  ------------------------------------------------------------ ---------------- ------------------------ ----------------- ------------------------ -------------------- ------------------------ ------- ------------------------ ------- ------------------------ -------
  *LEP*                                                                                                                                                                                                                                                             
   rs7799039\[G/A\]                                            3                1.133(0.966-1.328)       0.033             **1.241(1.044-1.474)**   0.47                 **1.282(1.043-1.576)**   0.099   1.073(0.907-1.270)       0.049   **1.133(1.024-1.254)**   0.085
   rs2167270\[G/A\]                                            2                0.898(0.760-1.060)       0.182             0.959(0.752-1.225)       0.672                0.911(0.702-1.183)       0.389   0.896(0.752-1.068)       0.203   0.935(0.828-1.055)       0.233
  *LEPR*                                                                                                                                                                                                                                                            
   rs1137100\[A/G\]                                            3                1.006(0.878-1.154)       0.883             1.065(0.854-1.329)       0.996                1.054(0.834-1.332)       0.977   0.993(0.860-1.147)       0.867   1.018(0.918-1.129)       0.93
   rs1137101\[A/G\]                                            2                **0.704(0.570-0.871)**   0.207             0.966(0.747-1.248)       0.609                0.774(0.581-1.033)       0.749   **0.680(0.541-0.853)**   0.148   **0.843(0.730-0.973)**   0.641
  *ADIPOQ*                                                                                                                                                                                                                                                          
   rs266729\[C/G\]                                             5                0.959(0.865-1.064)       0.001             1.114(0.913-1.360)       0.511                1.081(0.881-1.327)       0.330   0.937(0.841-1.045)       0.001   0.992(0.913-1.077)       0.007
   rs2241766\[T/G\]                                            4                **1.249(1.036-1.507)**   0.000             1.055(0.608-1.831)       0.157                1.150(0.654-2.020)       0.347   **1.266(1.044-1.535)**   0.000   **1.201(1.015-1.422)**   0.004
   rs1501299\[G/T\]                                            3                **0.806(0.669-0.973)**   0.182             0.940(0.689-1.282)       0.956                0.865(0.625-1.197)       0.770   **0.797(0.653-0.972)**   0.166   0.869(0.752-1.004)       0.297
   rs182052\[G/A\]                                             3                1.045(0.937-1.165)       0.272             1.031(0.907-1.171)       0.042                1.078(0.928-1.253)       0.052   1.03(0.919-1.156)        0.348   1.03(0.958-1.107)        0.111
   rs822395\[A/C\]                                             3                **0.805(0.652-0.995)**   0.868             1.107(0.805-1.522)       0.250                0.979(0.697-1.377)       0.314   **0.754(0.602-0.944)**   0.810   0.909(0.776-1.065)       0.73
   rs822396\[A/G\]                                             2                0.901(0.710-1.145)       0.213             **2.187(1.211-3.950)**   0.056                **2.068(1.133-3.774)**   0.093   0.798(0.620-1.026)       0.040   1.023(0.833-1.255)       0.779
  *ADIPOR1*                                                                                                                                                                                                                                                         
   rs10920531\[C/A\]                                           3                1.12(0.975-1.287)        0.565             **1.553(1.280-1.883)**   0.001                **1.66(1.335-2.065)**    0.008   1.01(0.873-1.168)        0.564   **1.184(1.075-1.305)**   0.144
   rs7539542\[G/C\]                                            3                1.056(0.916-1.219)       0.974             0.914(0.767-1.089)       0.676                1.004(0.809-1.247)       0.997   1.080(0.928-1.256)       0.842   0.998(0.905-1.100)       0.683
   rs12733285\[C/T\]                                           2                0.985(0.859-1.129)       0.012             0.962(0.776-1.192)       0.007                0.954(0.760-1.196)       0.002   0.986(0.854-1.139)       0.077   0.983(0.888-1.088)       0.002
   rs1342387\[C/T\]                                            2                0.872(0.678-1.120)       0.536             0.924(0.717-1.192)       0.440                0.859(0.632-1.168)       0.887   0.881(0.674-1.152)       0.341   0.920(0.787-1.076)       0.947
   rs2232853\[G/A\]                                            2                **0.723(0.571-0.916)**   0.009             **0.378(0.268-0.532)**   0.628                **0.340(0.234-0.494)**   0.528   0.911(0.707-1.173)       0.109   **0.638(0.535-0.760)**   0.002

*OR* odds ratio, *CI* confidence interval

P value of Q test for assessing heterogeneity.

Common synonyms for genetic polymorphisms: LEP G2548A(rs7799039), LEP A19G(rs2167270), LEPR K109R(rs1137100), LEPR Q223R(rs1137101)

In the meta-analysis (Table [1](#T1){ref-type="table"}), all studies were case-control design. Studies were conducted from 2003 to 2016. Among them, five were performed in USA, another two were performed in Portugal, and the rest four were performed in UK, Finland, China and Japan, respectively. The Newcastle-Ottawa Scale (NOS) scores ranged from 4 to 9. Polymorphisms with meta-analyzed statistics were presented in Table [2](#T2){ref-type="table"}, and those with single supporting study were pooled in Table [3](#T3){ref-type="table"}. The population number of case and control in each genetic variant and associated forest plots were also displayed ([Supplemental Data S1](#SD2){ref-type="supplementary-material"}, [Supplemental Data S2](#SD1){ref-type="supplementary-material"}). Besides, the genetic variants were found to be associated with PCa aggressiveness, e.g. pathological grade, castration resistance, recurrence and metastasis, and survival (Table [4](#T4){ref-type="table"}).

###### Pooled-review of the studies investigating associations between *LEP/LEPR/ADIPOQ/ADIPOR1/ADIPOR2* polymorphisms and prostate cancer risk

  Genetic polymorphisms                                                  Author    Year   Dominant model            Recessive model           Homozygote model          Heterozygote model       Allele contrast model
  ---------------------------------------------------------------------- --------- ------ ------------------------- ------------------------- ------------------------- ------------------------ ------------------------
  *LEP*                                                                                                                                                                                          
   rs1349419\[G/A\]                                                      Moore     2009   **0.771(0.635-0.936)**    0.930(0.729-1.186)        0.797(0.608-1.044)        **0.762(0.620-0.936)**   **0.865(0.757-0.988)**
   rs12535708\[C/A\]                                                     Moore     2009   **0.818(0.679-0.986)**    0.885(0.668-1.172)        0.804(0.597-1.082)        0.823(0.675-1.003)       **0.869(0.757-0.998)**
   rs12535747\[C/A\]                                                     Moore     2009   **0.808(0.671-0.973)**    0.872(0.660-1.152)        0.789(0.587-1.059)        **0.814(0.668-0.992)**   **0.860(0.749-0.987)**
   rs791620\[C/A\]                                                       Moore     2009   0.906(0.685-1.199)        \-                        \-                        0.906(0.685-1.199)       0.912(0.696-1.196)
   D7S1875(Microsatellite)\[S/L\][^\#^](#tfn_001){ref-type="table-fn"}   Gade      2006   **0.475((0.259-0.872)**   0.705(0.216-2.301)        0.534(0.160-1.778)        **0.464(0.243-0.885)**   **0.573(0.347-0.945)**
  *LEPR*                                                                                                                                                                                         
   rs1887285\[A/G\]                                                      Moore     2009   0.789(0.595-1.046)        2.106(0.646-6.865)        2.031(0.623-6.623)        **0.746(0.558-0.997)**   0.845(0.649-1.102)
   rs7883\[G/A\]                                                         Moore     2009   1.283(0.960-1.714)        4.403(0.513-37.764)       4.515(0.526-38.733)       1.246(0.929-1.670)       1.032(0.989-1.719)
   rs7602\[G/A\]                                                         Moore     2009   0.914(0.730-1.145)        2.260(0.802-6.367)        2.201(0.780-6.205)        0.879(0.699-1.105)       0.962(0.782-1.183)
   K656N(rs8179183)\[G/C\]                                               Ribeiro   2012   0.836(0.644-1.085)        1.251(0.631-2.479)        1.164(0.584-2.321)        0.807(0.616-1.057)       0.898(0.719-1.122)
   Exon-3(Microsatellite)\[S/L\][^\#^](#tfn_004){ref-type="table-fn"}    Gade      2006   **1.875(1.030-3.412)**    **5.516(1.857-16.383)**   **6.800(2.170-21.312)**   1.484(0.792-2.780)       **1.918(1.245-2.955)**
  *ADIPOQ*                                                                                                                                                                                       
   rs12495941\[G/T\]                                                     Dhillon   2011   1.008(0.857-1.186)        1.074(0.846-1.363)        1.069(0.828-1.379)        0.991(0.834-1.177)       1.022(0.908-1.151)
   rs168681205\[G/A\]                                                    Dhillon   2011   1.147(0.904-1.456)        0.702(0.222-2.218)        0.716(0.226-2.262)        1.169(0.917-1.490)       1.116(0.890-1.399)
   rs168681209\[C/A\]                                                    Dhillon   2011   0.884(0.721-1.082)        1.178(0.526-2.640)        1.149(0.512-2.577)        0.871(0.708-1.072)       0.907(0.752-1.095)
   rs17366568\[G/A\]                                                     Dhillon   2011   1.116(0.925-1.348)        1.284(0.621-2.655)        1.313(0.634-2.720)        1.106(0.913-1.341)       1.111(0.936-1.319)
   rs17366743\[T/C\]                                                     Moore     2009   1.086(0.737-1.599)        0.300(0.012-7.367)        0.302(0.012-7.413)        1.108(0.751-1.635)       1.061(0.726-1.550)
   rs2082940\[C/T\]                                                      Dhillon   2011   **0.785(0.647-0.954)**    0.526(0.273-1.012)        **0.504(0.262-0.971)**    **0.814(0.666-0.994)**   **0.780(0.654-0.931)**
   rs3774261\[G/A\]                                                      Dhillon   2011   0.969(0.823-1.142)        0.910(0.730-1.133)        0.905(0.711-1.151)        0.991(0.833-1.179)       0.960(0.856-1.077)
   rs3774262\[G/A\]                                                      Gu        2014   0.898(0.752-1.073)        **0.659(0.484-0.898)**    **0.649(0.471-0.895)**    0.966(0.801-1.166)       **0.863(0.752-0.989)**
   rs3821799\[C/T\]                                                      Dhillon   2011   0.898(0.755-1.068)        0.934(0.768-1.136)        0.879(0.701-1.102)        0.906(0.754-1.089)       0.934(0.835-1.045)
   rs7639352\[C/T\]                                                      Dhillon   2011   1.052(0.895-1.237)        1.017(0.757-1.366)        1.039(0.768-1.407)        1.055(0.889-1.252)       1.036(0.911-1.179)
   rs822391\[T/C\]                                                       Dhillon   2011   **0.812(0.687-0.960)**    0.879(0.588-1.315)        0.824(0.549-1.236)        **0.810(0.681-0.965)**   **0.845(0.733-0.975)**
   rs822393\[C/T\]                                                       Moore     2009   0.971(0.801-1.177)        0.825(0.646-1.054)        0.837(0.638-1.098)        1.026(0.835-1.261)       0.931(0.814-1.064)
  *ADIPOR1*                                                                                                                                                                                      
   rs16850799\[C/T\]                                                     Dhillon   2011   0.919(0.780-1.084)        0.949(0.668-1.348)        0.921(0.645-1.315)        0.919(0.773-1.092)       0.936(0.817-1.073)
  *ADIPOR2*                                                                                                                                                                                      
   rs1029629\[T/G\]                                                      Dhillon   2011   0.933(0.795-1.095)        0.975(0.740-1.284)        0.943(0.708-1.256)        0.931(0.786-1.012)       0.955(0.844-1.080)
   rs1044471\[C/T\]                                                      Dhillon   2011   1.013(0.848-1.210)        1.163(0.967-1.398)        1.131(0.907-1.410)        0.957(0.792-1.158)       1.063(0.950-1.189)
   rs1044825\[T/G\]                                                      Dhillon   2011   0.942(0.794-1.116)        1.084(0.880-1.335)        1.026(0.812-1.297)        0.912(0.761-1.092)       0.997(0.889-1.118)
   rs1058322\[C/T\]\]                                                    Dhillon   2011   0.945(0.805-1.110)        0.833(0.632-1.097)        0.823(0.618-1.096)        0.975(0.823-1.156)       0.932(0.823-1.055)
   rs10773983\[G/A\]                                                     Dhillon   2011   1.010(0.860-1.187)        1.018(0.776-1.335)        1.022(0.770-1.357)        1.008(0.852-1.193)       1.010(0.894-1.140)
   rs10773986\[A/G\]                                                     Dhillon   2011   0.934(0.795-1.097)        1.057(0.810-1.380)        1.014(0.768-1.339)        0.916(0.772-1.085)       0.972(0.860-1.100)
   rs11061946\[C/T\]                                                     Dhillon   2011   1.163(0.926-1.461)        0.614(0.200-1.882)        0.629(0.205-1.928)        1.191(0.944-1.502)       1.123(0.905-1.393)
   rs11061973\[G/A\]                                                     Dhillon   2011   1.041(0.872-1.244)        0.976(0.579-1.643)        0.987(0.585-1.666)        1.046(0.871-1.257)       1.030(0.880-1.205)
   rs12826079\[C/T\]                                                     Dhillon   2011   1.006(0.797-1.271)        1.650(0.598-4.555)        1.647(0.596-4.547)        0.982(0.773-1.246)       1.031(0.827-1.284)
   rs7967137\[T/C\]                                                      Dhillon   2011   0.961(0.794-1.163)        0.976(0.514-1.853)        0.968(0.510-1.841)        0.961(0.789-1.169)       0.966(0.812-1.149)
   rs7975600\[A/T\]                                                      Dhillon   2011   0.884(0.738-1.060)        0.915(0.553-1.516)        0.889(0.536-1.475)        0.884(0.733-1.067)       0.900(0.766-1.056)

*OR* odds ratio, *CI* confidence interval

S stands for short allele, and L stands for long allele.

###### Pooled-review of the studies investigating associations between genetic variants and prostate cancer aggressiveness

  Genetic polymorphisms[^\#^](#tfn_005){ref-type="table-fn"}   Author      Year   Associations of minor allele of polymorphisms with PCa aggressiveness (unless otherwise stated)
  ------------------------------------------------------------ ----------- ------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  *LEP*                                                                           
   rs7799039\[G/A\]                                            Ribeiro     2004   Over represented in PCa patients with advanced disease (OR 1.91, 95%CI 1.24-2.59).
   rs10244329\[A/T\]                                           Reese       2010   Associated with PCa recurrence after definitive treatment (HR 0.49, 95%CI 0.28-0.84, P=0.010).
  *LEPR*                                                                          
   rs8179183\[G/C\]                                            Monteiro    2010   Associated with higher Gleason score (P=0.008).
   rs1137100\[A/G\]                                            Monteiro    2010   Lys carrier had lower time-to-bone metastasis in multivariate analysis (HR 0.37, 95% CI 0.14-0.95, P=0.039).
                                                               Lin         2011   Associated with a decrease in PCa specific mortality (HR 0.82, 95%CI 0.67-1.00, P=0.027) in the Swedish cohort.
                                                               Kapustina   2014   Distinguish PCa patients with high grade (Gleason score ≥7) or low grade (Gleason score \<7) cancer.
   rs1137101\[A/G\]                                            Monteiro    2009   Associated with a higher Gleason score (P=0.022) and shorter time-to-relapse (P=0.006).
                                                               Ribeiro     2012   In multivariate model, AA was associated with high-grade PCa (Gleason score ≥7) (OR 1.56, 95%CI 1.15-2.12).
  *ADIPOQ*                                                                        
   rs1501299\[G/T\]                                            Cunha       2010   Associated with increased risk for higher Gleason score (OR 1.99, 95%CI 1.2-3.3, P=0.004), shorter time to hormonal castration resistance (TT vs. G, P=0.006).
   rs182052\[G/A\]                                             Gu          2015   Associated with increased risk of biochemical recurrence (AA vs GG, HR 2.44, 95%CI 1.57-3.79, P=6×10^-5^).
  *ADIPOR2*                                                                       
   rs1044471\[C/T\]                                            Stark       2011   Associated with time to lethal PCa (CT vs CC, HR 0.6, 95%CI 0.4-0.9; TT vs CC, HR 0.8, 95%CI 0.6-1.2).

*OR* odds ratio, *CI* confidence interval, *PCa* prostate cancer

Common synonyms for genetic polymorphisms: LEP G2548A(rs7799039), LEPR K656N (rs8179183), LEPR K109R(rs1137100), LEPR Q223R(rs1137101)

LEP polymorphisms and PCa {#s2_2}
-------------------------

A total of eight *LEP* polymorphisms were enrolled, with key information outlined in Figure [2](#F2){ref-type="fig"}. *LEP* rs7799039 A allele was correlated with higher risk of PCa (allele contrast: OR 1.133, 95%CI 1.024-1.254, Table [2](#T2){ref-type="table"}), which was also over represented in advanced diseases (Table [4](#T4){ref-type="table"}). On the contrary, the variants of *LEP* rs1349419 (allele contrast: OR 0.865, 95%CI 0.757-0.988), *LEP* rs12535708 (allele contrast: OR 0.869, 95%CI 0.757-0.998), *LEP* rs12535747 (allele contrast: OR 0.860, 95%CI 0.749-0.987) and *LEP* D7S1875 (allele contrast: OR 0.573, 95%CI 0.347-0.945) were associated with decreased risk of total PCa (Table [3](#T3){ref-type="table"}). Besides, *LEP* rs10244329 variant was associated with lower recurrence rate after definitive treatment (Table [4](#T4){ref-type="table"}).

![Diagram of *LEP* polymorphisms and prostate cancer](oncotarget-07-81049-g002){#F2}

LEPR polymorphisms and PCa {#s2_3}
--------------------------

A total of eight *LEPR* polymorphisms were enrolled, with key data displayed in Figure [3](#F3){ref-type="fig"}. *LEPR* rs1137101 G allele was associated with lower PCa risk (allele contrast: OR 0.843, 95%CI 0.730-0.973, Table [2](#T2){ref-type="table"}), while it was proved to be associated with worse pathological grade and prognosis (Table [4](#T4){ref-type="table"}). *LEPR* Exon-3 long allele variant was proved to increase PCa risk (allele contrast: OR 1.918, 95%CI 1.245-2.955, Table [3](#T3){ref-type="table"}). Besides, *LEPR* rs8179183 variant was associated with higher Gleason score, and *LEPR* rs1137100 polymorphism was related to both pathological grade and patient survival (Table [4](#T4){ref-type="table"}).

![Diagram of *LEPR* polymorphisms and prostate cancer](oncotarget-07-81049-g003){#F3}

ADIPOQ polymorphisms and PCa {#s2_4}
----------------------------

A total of 18 polymorphisms in gene *ADIPOQ* were enrolled, with key data displayed in Figure [4](#F4){ref-type="fig"}. *ADIPOQ* rs2241766 G allele was correlated with higher PCa risk (allele contrast: OR 1.201, 95%CI 1.015-1.422, Table [2](#T2){ref-type="table"}). On the contrary, the variants of *ADIPOQ* rs2082940 (allele contrast: OR 0.780, 95%CI 0.654-0.931), *ADIPOQ* rs3774262 (allele contrast: OR 0.863, 95%CI 0.752-0.989) and *ADIPOQ* rs822391 (allele contrast: OR 0.845, 95%CI 0.733-0.975) were negatively associated with cancer risk (Table [3](#T3){ref-type="table"}). *ADIPOQ* rs1501299 variant was reported to be associated with higher Gleason score and shorter time to castration resistance of PCa (Table [4](#T4){ref-type="table"}). Besides, *ADIPOQ* rs182052 variant was associated with increased biochemical recurrence of PCa (Table [4](#T4){ref-type="table"}).

![Diagram of *ADIPOQ* polymorphisms and prostate cancer](oncotarget-07-81049-g004){#F4}

ADIPOR1/ADIPOR2 polymorphisms and PCa {#s2_5}
-------------------------------------

Both *ADIPOR1* and *ADIPOR2* encoded proteins that served as receptors for adiponectin. A total of six variants in gene *ADIPOR1* and 11 variants in gene *ADIPOR2* were enrolled and displayed in Figure [5](#F5){ref-type="fig"}. *ADIPOR1* rs10920531 variant was correlated with higher PCa risk (allele contrast: OR 1.184, 95%CI 1.075-1.305, Table [2](#T2){ref-type="table"}). However, a negative association was witnessed between *ADIPOR1* rs2232853 variant and cancer risk (allele contrast: OR 0.638, 95%CI 0.535-0.760, Table [2](#T2){ref-type="table"}). We failed to detect any associations between *ADIPOR2* gene polymorphisms and risk of PCa. Meanwhile, *ADIPOR2* rs1044471 variant was negatively associated with time to lethal PCa.

![Diagram of *ADIPOR1*/*ADIPOR2* polymorphisms and prostate cancer](oncotarget-07-81049-g005){#F5}

DISCUSSION {#s3}
==========

Various clinical and molecular studies were conducted to deliberate the associations among leptin, adiponectin and PCa, while controversies still existed and exact mechanisms remained largely unknown. From a genetic perspective, the present study conducted an updated meta-analysis and pooled-review. We enrolled 49 genetic variants in gene *LEP*, *LEPR, ADIPOQ, ADIPOR1* and *ADIPOR2*, to investigate the relationships between these polymorphisms and PCa. The meta-analysis yielded five polymorphisms that associated with PCa risk according to allele contrast model. Meanwhile, the pooled-review outlined eight variants that affected cancer risk and another eight polymorphisms that affected cancer aggressiveness.

The *LEP* gene, encoded leptin that was associated with obesity and carcinogenesis \[[@R13]\]. In present study, we discovered that minor allele in *LEP* rs7799039 (G2548A) increased both the prevalence and aggressiveness of PCa. The increasing trend in cancer risk was in accordance with previous studies \[[@R37], [@R38]\]. The rs7799039 was located at promoter sequence of gene *LEP*. Several studies demonstrated that the variants might elevate the serum leptin level through transcriptional level, and increase human body weight as well \[[@R39], [@R40]\]. Higher leptin level, in turn, contributed to cancer growth and development via stimulating inflammation, angiogenesis, proliferation and epithelial-mesenchymal transition \[[@R10], [@R41]\].

Leptin exerted its downstream functioning through binding to leptin receptor (encoded by gene *LEPR*). Like *LEP*, *LEPR* was also highly polymorphic, with a number of single nucleotide polymorphisms identified. The present study revealed that *LEPR* rs1137101 (Q223R) variants were correlated with decreased PCa risk, whereas worse pathological grade and prognosis. The previous meta-analysis discovered that rs1137101 might increase the susceptibility to cancers in Asian and African patients, while decreasing the susceptibility in Caucasians, suggesting that race might explain for the heterogeneity and inconsistency among different studies \[[@R42]\]. On the other hand, the associations between rs1137101 and different cancers remained inconsistent \[[@R37], [@R42]\]. In the present study, the enrolled population were all Caucasians. Whether the negative associations with cancer risk contributed to Caucasian race or cancer type required further validation. It was well studied that rs1137101 mutation (A to G transversion) encoded a glutamine to arginine substitution in the N-terminal CRH1 domain \[[@R43]\], which was proved dispensable for a high affinity interaction with leptin binding \[[@R44]\]. However, the mutation might alter downstream signaling (e.g. STAT3, JAK2), surface expression, or receptor trafficking \[[@R44]--[@R46]\], which might partly underlie the mechanisms for worse pathological grade and prognosis of PCa in the present study.

*ADIPOQ* gene was also highly polymorphic, with at least 620 reported polymorphisms. Some of the polymorphisms were studied for their associations with cancer risk \[[@R47]\]. In the present study, we demonstrated that *ADIPOQ* rs2241766 variant was associated with increased risk of PCa. Of note, the outcome was opposite to those found in colorectal cancer, where the variant allele was identified as a protective factor against cancer \[[@R14], [@R47]\]. The discrepancy remained unknown. To our knowledge, the rs2241766 variant, a synonymous polymorphism at exon 2, might alter mRNA levels by regulation of mRNA splicing or stability \[[@R48]\]. Recently, a meta-analysis discovered that G allele of rs2241766 increased the risk of metabolic syndrome \[[@R49]\]. Meanwhile, metabolic syndrome was closely associated with cancer development and progression \[[@R50]\], which provided a probable mechanism underlying the present outcomes.

Adiponectin receptor 1 and 2 were often differentially expressed in cancers \[[@R14]\]. In the present study, we found no correlation among *ADIPOR1* rs7539542, rs12733285, rs1342387 and risk of PCa, which was in line with the previous study \[[@R17]\]. Of note, we discovered that *ADIPOR1* rs10920531 polymorphism was associated with increased risk of PCa, while *ADIPOR1* rs2232853 variant decreased the risk of PCa. These two polymorphisms were firstly reported that were associated with cancer risk. Since the limitation of related studies, the outcomes required more validation and the underlying mechanisms demand further exploration.

Several limitations existed in the present study. First, the number of studies addressing each polymorphism was limited, and therefore confined us from conducting more meaningful subgroup analyses, e.g. race. Second, the baseline body mass index, serum leptin and adiponectin level were not reported in each study, which might bias the outcomes and constrain us to draw more conclusions. Consequently, more well designed studies with different population were warranted to better identify these complexities.

In conclusion, the present study comprehensively summarized the associations of genetic polymorphisms in *LEP*, *LEPR*, *ADIPOQ*, *ADIPOR1* and *ADIPOR2* with the risk and aggressiveness of PCa. We discovered that *LEP* rs7799039, *ADIPOQ* rs2241766 and *ADIPOR1* rs10920531 variants were correlated with increased risk of PCa, while *LEPR* rs1137101 and *ADIPOR1* rs2232853 variants were associated with decreased risk of PCa in the meta-analysis. From the pooled-review, we further identified eight variants associated with cancer risk and another eight variants associated with cancer aggressiveness, respectively. These observations provided rich evidence that leptin and adiponectin, along with their receptors, were involved in the development and progression of PCa. We expected to help prediction of prevalence and prognosis of PCa, as well as generation of novel targeted therapy, especially in obese patients with impaired leptin and adiponectin signaling.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We conducted a comprehensive literature search in PubMed and EMBASE database up to May 1^st^, 2016. Searching strategy involved "prostatic neoplasms OR prostatic cancer OR prostate cancer OR PCa", "polymorphism\* OR variant\* OR SNP", "leptin OR *LE*P OR *LEPR* OR adiponectin OR *ADIPOQ* OR *ADIPOR\**" and various combinations of these terms. The search was conducted without limitations of language. Reviews, meta-analyses, original articles, and other studies of interest were further examined to identify additional eligible studies.

Selection criteria {#s4_2}
------------------

The eligible studies were included according to the following criteria: (1) studies investigating the associations between *LEP*/*LEPR*/*ADIPOQ*/*ADIPOR1*/*ADIPOR2* polymorphisms and PCa risk or aggressiveness; (2) case-control or cohort studies; (3) sufficient data, including the accurate population number of specific alleles, genotypes and microsatellites; (4) genotype frequencies in control groups should be examined by the Hardy-Weinberg equilibrium (HWE). If serial studies of the same study population were reported, the most recent study or the study with the largest population should be adopted. The exclusion criteria included: (1) animal or molecular studies; (2) reviews, meta-analyses or case reports; (3) insufficient information published in the study; (4) duplicated studies.

Data extraction and quality assessment {#s4_3}
--------------------------------------

Two investigators (Hu and Xu) independently evaluated the eligibility of all retrieved studies, and extracted key information. The collected data included: author\'s name, year of publication, study population, study design, genotyping methods, case and control population, and polymorphisms investigated. NOS was adopted to evaluate the quality of all eligible studies \[[@R51]\]. The nine-star NOS was based on three dimensions: study group selection, comparability of cases and controls, and exposure of cases and controls. The disagreements during data extraction and quality assessment were resolved by consensus.

Meta-analysis and pooled review {#s4_4}
-------------------------------

In the meta-analysis, the pooled odds ratio (OR) with 95% confidence interval (95%CI) was calculated to evaluate the correlation between genetic polymorphisms and total PCa risk according to allele contrast, homozygote, heterozygote, dominant and recessive models. The inter-study heterogeneity was verified by Q and I^2^ statistics. Fixed-effect model was adopted to estimate the OR and 95%CI when heterogeneity was low, otherwise random-effect model was adopted. Besides, we conducted a pooled-review for studies discussing risk or aggressiveness of PCa that could not be included in the meta-analysis. All analyses were performed using the STATA/SE 12.0 software (StataCorp, College Station, TX, USA). Statistical significance was defined as a two-tailed p-value \<0.05.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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